Share Price and Basic Stock Data
Last Updated: October 28, 2025, 8:48 pm
| PEG Ratio | 0.16 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Fermenta Biotech Ltd operates within the pharmaceuticals sector, with a current share price of ₹267 and a market capitalization of ₹787 Cr. The company has shown fluctuating revenue trends over recent quarters, with sales recorded at ₹105 Cr in March 2023, declining to ₹57 Cr in September 2023, before rebounding to ₹99 Cr in December 2023. The trailing twelve months (TTM) sales stood at ₹528 Cr, reflecting a recovery from previous years, where sales were ₹349 Cr in March 2023 and ₹335 Cr in March 2024. The company’s revenue from operations per share was ₹160.95 for the year ending March 2025. Over the years, Fermenta has seen a significant growth trajectory, especially from ₹139 Cr in March 2014 to ₹468 Cr in March 2025, indicating a compound annual growth rate that outpaces many industry peers. However, the quarterly volatility raises concerns regarding consistency in revenue generation, highlighting the need for strategic planning and market adaptation.
Profitability and Efficiency Metrics
Fermenta Biotech’s profitability metrics present a mixed picture. The company reported a net profit of ₹104 Cr in the most recent annual data, translating to an impressive price-to-earnings (P/E) ratio of 7.53. However, the operating profit margin (OPM) has oscillated significantly, standing at 21% overall but showing a decline in certain quarters, notably a negative OPM of -24% in September 2023. The return on equity (ROE) is robust at 24.9%, while the return on capital employed (ROCE) stands at 23.0%, indicating effective utilization of capital. The interest coverage ratio (ICR) of 8.57x suggests the company is well-positioned to meet its interest obligations. Nevertheless, the cash conversion cycle (CCC) of 189 days indicates inefficiencies in working capital management, as the company takes longer to convert its investments back into cash, which could impact liquidity if not addressed.
Balance Sheet Strength and Financial Ratios
Fermenta Biotech’s balance sheet demonstrates a solid financial foundation, with total reserves reported at ₹348 Cr against borrowings of ₹115 Cr, reflecting a low long-term debt-to-equity ratio of 0.04. This indicates minimal reliance on debt for financing operations, contributing to financial stability. The current ratio of 1.58 and quick ratio of 0.99 suggest adequate liquidity to cover short-term liabilities, although the quick ratio is slightly below the ideal benchmark of 1.0. The company’s book value per share has risen to ₹124.33 in March 2025, up from ₹98.76 in March 2024, indicating an increase in shareholder value. The price-to-book value (P/BV) ratio of 2.20x suggests that the stock is trading at a premium relative to its book value, a typical scenario for companies with strong growth prospects. However, the enterprise value (EV) of ₹831.46 Cr against net operating revenue of ₹468 Cr indicates that the market may be priced in future growth expectations, which carries inherent risks if performance does not meet these expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fermenta Biotech reflects a strong promoter holding of 64.08%, which can instill confidence among investors regarding management stability and commitment. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold minimal stakes of just 0.02% and 0.00%, respectively, indicating a lack of institutional interest, which is often seen as a red flag by potential investors. The public holding stands at 35%, with a gradual decline in the number of shareholders from 17,971 in September 2022 to 12,845 by June 2025, suggesting a potential disenfranchisement among smaller investors. This could be attributed to the volatility in performance metrics and the company’s need to enhance transparency and communication with its shareholders. The concentration of ownership may lead to risks associated with decision-making and could deter new investors from entering the stock, adversely affecting liquidity.
Outlook, Risks, and Final Insight
Looking forward, Fermenta Biotech has the potential for growth, particularly given its strong profitability metrics and efficient capital utilization. However, the company faces several risks, including market volatility affecting revenue stability and operational inefficiencies reflected in the cash conversion cycle. Additionally, the lack of institutional interest could hinder stock performance and investor confidence. The company must focus on enhancing operational efficiencies, particularly in working capital management, to improve cash flow. Strengthening communication with shareholders and attracting institutional investors will be crucial for long-term growth and stability. If Fermenta successfully navigates these challenges, it could leverage its strong market position to capitalize on future opportunities in the pharmaceuticals sector, while a failure to address these risks could lead to a stagnation in growth and declining investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fermenta Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,782.64 Cr | 1,180.72 | 50.39 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 98 | 55 | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 |
| Expenses | 87 | 95 | 65 | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 |
| Operating Profit | 5 | 3 | -10 | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 |
| OPM % | 5% | 3% | -18% | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% |
| Other Income | 4 | 3 | -19 | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 |
| Interest | 4 | 5 | 5 | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 |
| Depreciation | 7 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Profit before tax | -2 | -8 | -41 | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 |
| Tax % | 8% | 6% | -8% | 373% | 0% | 0% | 38% | 885% | 0% | 6% | 16% | -4% | 23% |
| Net Profit | -3 | -8 | -38 | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 |
| EPS in Rs | -0.88 | -2.75 | -12.70 | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 |
Last Updated: August 19, 2025, 3:45 pm
Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 136.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 136.00 Cr., marking a decrease of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Mar 2025) to 21.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from -4.00% (Mar 2025) to 23.00%, marking an increase of 27.00%.
- For Net Profit, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.42. The value appears to be declining and may need further review. It has decreased from 11.68 (Mar 2025) to 7.42, marking a decrease of 4.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 528 |
| Expenses | 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 390 |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 137 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 26% |
| Other Income | 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 18 |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 14 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 24 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 117 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | |
| Net Profit | 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 104 |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 35.51 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -90.00% | 100.00% | -550.00% | 611.11% | 154.35% | -48.72% | -28.33% | -65.12% | -453.33% | 54.72% | 416.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 190.00% | -650.00% | 1161.11% | -456.76% | -203.07% | 20.38% | -36.78% | -388.22% | 508.05% | 361.95% |
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 7% |
| 3 Years: | 74% |
| TTM: | 532% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -3% |
| 3 Years: | 10% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 25% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: July 25, 2025, 1:18 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 |
| Reserves | 130 | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 |
| Borrowings | 65 | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 |
| Other Liabilities | 61 | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 |
| Total Liabilities | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 |
| Fixed Assets | 87 | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 |
| CWIP | 36 | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 |
| Investments | 17 | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 |
| Other Assets | 118 | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 |
| Total Assets | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 |
Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2024) to 348.00 Cr., marking an increase of 74.00 Cr..
- For Borrowings, as of Mar 2025, the value is 115.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 139.00 Cr. (Mar 2024) to 115.00 Cr., marking a decrease of 24.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 137.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 120.00 Cr. (Mar 2024) to 137.00 Cr., marking an increase of 17.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 614.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 227.00 Cr.. The value appears to be declining and may need further review. It has decreased from 269.00 Cr. (Mar 2024) to 227.00 Cr., marking a decrease of 42.00 Cr..
- For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 14.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 372.00 Cr.. The value appears strong and on an upward trend. It has increased from 277.00 Cr. (Mar 2024) to 372.00 Cr., marking an increase of 95.00 Cr..
- For Total Assets, as of Mar 2025, the value is 614.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..
Notably, the Reserves (348.00 Cr.) exceed the Borrowings (115.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -39.00 | -55.00 | -68.00 | -75.00 | -80.00 | -53.00 | -158.00 | -149.00 | -177.00 | -202.00 | -111.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 |
| Working Capital Days | 9 | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.77 |
| Diluted EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.69 |
| Cash EPS (Rs.) | 34.50 | 0.24 | -8.77 | 14.08 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Revenue From Operations / Share (Rs.) | 160.95 | 116.25 | 121.27 | 138.15 | 130.79 |
| PBDIT / Share (Rs.) | 41.69 | 13.62 | 8.88 | 24.12 | 31.17 |
| PBIT / Share (Rs.) | 33.39 | 5.06 | -0.90 | 15.26 | 24.13 |
| PBT / Share (Rs.) | 28.53 | -3.42 | -17.98 | 9.34 | 17.90 |
| Net Profit / Share (Rs.) | 26.19 | -8.31 | -18.56 | 5.22 | 14.74 |
| NP After MI And SOA / Share (Rs.) | 26.35 | -7.99 | -17.85 | 5.35 | 15.77 |
| PBDIT Margin (%) | 25.90 | 11.71 | 7.32 | 17.46 | 23.83 |
| PBIT Margin (%) | 20.74 | 4.34 | -0.74 | 11.04 | 18.44 |
| PBT Margin (%) | 17.72 | -2.94 | -14.82 | 6.76 | 13.68 |
| Net Profit Margin (%) | 16.27 | -7.15 | -15.30 | 3.77 | 11.27 |
| NP After MI And SOA Margin (%) | 16.37 | -6.86 | -14.71 | 3.87 | 12.06 |
| Return on Networth / Equity (%) | 21.19 | -7.98 | -16.36 | 4.15 | 12.62 |
| Return on Capital Employeed (%) | 24.19 | 3.89 | -0.61 | 8.81 | 14.56 |
| Return On Assets (%) | 12.50 | -4.20 | -8.09 | 2.18 | 6.62 |
| Long Term Debt / Equity (X) | 0.04 | 0.14 | 0.26 | 0.30 | 0.30 |
| Total Debt / Equity (X) | 0.30 | 0.45 | 0.68 | 0.63 | 0.57 |
| Asset Turnover Ratio (%) | 0.80 | 0.56 | 0.52 | 0.55 | 0.57 |
| Current Ratio (X) | 1.58 | 1.40 | 1.21 | 1.52 | 1.48 |
| Quick Ratio (X) | 0.99 | 0.89 | 0.58 | 0.74 | 0.70 |
| Inventory Turnover Ratio (X) | 4.45 | 0.70 | 0.77 | 0.91 | 1.06 |
| Dividend Payout Ratio (NP) (%) | 4.69 | -15.65 | -7.00 | 46.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.57 | 217.49 | -15.50 | 17.58 | 0.00 |
| Earning Retention Ratio (%) | 95.31 | 115.65 | 107.00 | 53.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.43 | -117.49 | 115.50 | 82.42 | 0.00 |
| Interest Coverage Ratio (X) | 8.57 | 2.31 | 1.23 | 4.07 | 5.00 |
| Interest Coverage Ratio (Post Tax) (X) | 6.38 | 0.02 | -0.20 | 1.88 | 3.37 |
| Enterprise Value (Cr.) | 831.46 | 505.89 | 464.45 | 795.24 | 883.96 |
| EV / Net Operating Revenue (X) | 1.77 | 1.51 | 1.33 | 2.00 | 2.34 |
| EV / EBITDA (X) | 6.84 | 12.87 | 18.12 | 11.43 | 9.83 |
| MarketCap / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| Retention Ratios (%) | 95.30 | 115.65 | 107.00 | 53.31 | 0.00 |
| Price / BV (X) | 2.20 | 1.51 | 0.98 | 1.59 | 2.00 |
| Price / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| EarningsYield | 0.09 | -0.05 | -0.16 | 0.02 | 0.06 |
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
- For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
- For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
- For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
- For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
- For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.19. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.19, marking an increase of 29.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
- For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.45. This value is within the healthy range. It has increased from 0.70 (Mar 24) to 4.45, marking an increase of 3.75.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 4.69, marking an increase of 20.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 3.57, marking a decrease of 213.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.31. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.31, marking a decrease of 20.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.43. This value exceeds the healthy maximum of 70. It has increased from -117.49 (Mar 24) to 96.43, marking an increase of 213.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 831.46. It has increased from 505.89 (Mar 24) to 831.46, marking an increase of 325.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.77, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 6.84. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.84, marking a decrease of 6.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 95.30. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.30, marking a decrease of 20.35.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.20, marking an increase of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
- Net Profit Margin: 16.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.19% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.19% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 7.53 (Industry average Stock P/E: 50.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1501, Thane One, DIL Complex, Thane Maharashtra 400610 | info@fermentabiotech.com https://www.fermentabiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep M Chandan | Chairman & Ind.Dire (Non-Exe) |
| Mr. Krishna Datla | Exe.Vice Chairman & Whole Time Director |
| Mr. Prashant Nagre | Managing Director |
| Mr. Satish Varma | Executive Director |
| Ms. Anupama Datla Desai | Executive Director |
| Ms. Rajeshwari Datla | Non Executive Director |
| Mr. Pramod Kasat | Ind. Non-Executive Director |
| Ms. Rajashri Ojha | Ind. Non-Executive Director |
| Mr. Ramanand Mundkur | Independent Director |
FAQ
What is the intrinsic value of Fermenta Biotech Ltd?
Fermenta Biotech Ltd's intrinsic value (as of 28 October 2025) is 186.23 which is 30.25% lower the current market price of 267.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 787 Cr. market cap, FY2025-2026 high/low of 449/219, reserves of ₹348 Cr, and liabilities of 614 Cr.
What is the Market Cap of Fermenta Biotech Ltd?
The Market Cap of Fermenta Biotech Ltd is 787 Cr..
What is the current Stock Price of Fermenta Biotech Ltd as on 28 October 2025?
The current stock price of Fermenta Biotech Ltd as on 28 October 2025 is 267.
What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is 449/219.
What is the Stock P/E of Fermenta Biotech Ltd?
The Stock P/E of Fermenta Biotech Ltd is 7.53.
What is the Book Value of Fermenta Biotech Ltd?
The Book Value of Fermenta Biotech Ltd is 123.
What is the Dividend Yield of Fermenta Biotech Ltd?
The Dividend Yield of Fermenta Biotech Ltd is 0.94 %.
What is the ROCE of Fermenta Biotech Ltd?
The ROCE of Fermenta Biotech Ltd is 23.0 %.
What is the ROE of Fermenta Biotech Ltd?
The ROE of Fermenta Biotech Ltd is 24.9 %.
What is the Face Value of Fermenta Biotech Ltd?
The Face Value of Fermenta Biotech Ltd is 5.00.